BEXMAB

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Arms / Cohorts

Experimental:Phase 1 - Intermediate/high risk MDS, CMML 10-19%, MDS/CMML failure to HMA, r/r AML

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental:Phase 1 - Newly diagnosed AML patients non-fit for induction therapy

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental:Phase 2 - Intermediate/high risk MDS, CMML, MDS/CMML failure to HMA, r/r AML & newly diagnosed AML

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Patient Screener(888) 803-1766

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.